期刊
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
卷 28, 期 4, 页码 615-621出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/ATVBAHA.107.158154
关键词
thrombospondin-1; CD47; nitric oxide; ischemia; platelet aggregation
资金
- NATIONAL CANCER INSTITUTE [Z01SC009172] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054390, R56HL054390] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573] Funding Source: NIH RePORTER
- Intramural NIH HHS Funding Source: Medline
- NHLBI NIH HHS [HL54390, R56 HL054390, R01 HL054390-09A2, R01 HL054390] Funding Source: Medline
- NIGMS NIH HHS [R01 GM057573, GM57573, R01 GM057573-08] Funding Source: Medline
CD47, originally named integrin-associated protein, is a receptor for thrombospondin-1. A number of important roles for CD47 have been defined in regulating the migration, proliferation, and survival of vascular cells, and in regulation of innate and adaptive immunity. The recent discovery that thrombospondin-1 acts via CD47 to inhibit nitric oxide signaling throughout the vascular system has given new importance and perhaps a unifying mechanism of action to these enigmatic proteins. Here we trace the development of this exciting new paradigm for CD47 function in vascular physiology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据